In the Tumor Microenvironment, ETS1 Is an Oncogenic Immune Protein: An Integrative Pancancer Analysis

Zixuan Wu; Yanhui Jiang; Xuyan Huang; Minjie Cai; Kai Yuan; Peidong Huang; Zuhong Wang

doi:10.1155/2022/7730433

In the Tumor Microenvironment, ETS1 Is an Oncogenic Immune Protein: An Integrative Pancancer Analysis

Evid Based Complement Alternat Med. 2022 Apr 15:2022:7730433. doi: 10.1155/2022/7730433. eCollection 2022.

Authors

Zixuan Wu¹, Yanhui Jiang¹, Xuyan Huang¹, Minjie Cai², Kai Yuan³, Peidong Huang³, Zuhong Wang⁴

Affiliations

¹ Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
² Shantou Health School, Shantou 515061, Guangdong Province, China.
³ Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China.
⁴ Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650011, Yunnan Province, China.

Abstract

Background: Previous research suggested that ETS1 (ETS proto-oncogene 1, transcription factor) could be useful for cancer immunotherapy. The processes underlying its therapeutic potential, on the other hand, have yet to be thoroughly investigated. The purpose of this study was to look into the relationship between ETS1 expression and immunity.

Methods: TCGA and GEO provide raw data on 33 different cancers as well as GSE67501, GSE78220, and IMvigor210. In addition, we looked at ETS1's genetic changes, expression patterns, and survival studies. The linkages between ETS1 and TME, as well as its association with immunological processes/elements and the major histocompatibility complex, were explored to effectively understand the role of ETS1 in cancer immunotherapy. Three distinct immunotherapeutic cohorts were employed to examine the relationship between ETS1 and immunotherapeutic response.

Results: ETS1 expression was shown to be high in tumor tissue. ETS1 overexpression is linked to a worse clinical outcome in individuals with overall survival. Immune cell infiltration, immunological modulators, and immunotherapeutic signs are all linked to ETS1. Overexpression of ETS1 is linked to immune-related pathways. However, no statistically significant link was found between ETS1 and immunotherapeutic response.

Conclusions: ETS1 may be a reliable biomarker for tumor prognosis and a viable prospective therapeutic target for human cancer immunotherapy (e.g., KIRP, MESO, BLCA, KIRC, and THYM).